One in eight people who receive a donor lung do not survive the first year.
In Oslo, Crown Princess Mette-Marit of Norway has received a lung transplant after years of living with pulmonary fibrosis — a disease that had quietly stolen her breath and, by this spring, left her doctors believing she had little time remaining. The surgery, completed without complication, marks not an ending but a threshold: the beginning of a long, medically uncertain recovery that will demand as much from her body as the illness itself. Her story is one many quietly share — the race between deterioration and intervention, between waiting and the arrival of a second chance.
- Mette-Marit was placed on the transplant waiting list just twelve days before surgery, a clinical signal that her doctors believed she had roughly a year left to live without a new lung.
- Her public appearances had dwindled to almost nothing, and by May she was seen breathing through an oxygen tube — a visible, unsettling sign to Norwegians that their crown princess was in serious decline.
- The surgery succeeded, but the road ahead is medically precarious: one in eight transplant recipients do not survive the first year, and lifelong immunosuppressive medication is now her permanent reality.
- Prince Haakon is restructuring his official duties to remain by her side during the most critical weeks of post-transplant monitoring, when rejection risk is at its highest.
- The relief of a successful operation is shadowed by family turmoil — her son Marius was sentenced to four years in prison just two days before the transplant news broke, his requests for compassionate release denied.
- Royal historian Ole-Jørgen Schulsrud-Hansen called the transplant the removal of 'one of the most serious obstacles' to her future, capturing the nation's cautious but genuine exhale.
Crown Princess Mette-Marit of Norway is recovering in an Oslo hospital after a successful lung transplant, the royal household announced this week. The 52-year-old had been living with pulmonary fibrosis since 2018 — a progressive disease that stiffens lung tissue and makes breathing increasingly difficult. In recent months her condition had accelerated sharply, and by mid-May, when she last appeared in public, she was reliant on supplemental oxygen. Twelve days before the surgery, her doctors placed her on the transplant waiting list — a designation that carried a clear clinical message: without intervention, she likely had roughly a year to live.
Lung specialist Are Holm confirmed the procedure went without complication. Mette-Marit will remain hospitalized for several weeks, the standard protocol during the period when the body's rejection response is most intense. Prince Haakon has begun adjusting his official schedule to be present throughout her recovery.
The surgery arrived amid painful circumstances for the royal family. Just two days before the announcement, Mette-Marit's adult son Marius Borg Høiby was sentenced to four years in prison on rape charges. Though not a royal himself, his legal team had repeatedly sought his temporary release to support his mother during her health crisis — requests that were denied. His sentencing cast a long shadow over what might otherwise have been a moment of uncomplicated relief.
What lies ahead remains medically uncertain. Transplant recipients must take immunosuppressive drugs for life, and the statistics are sobering: one in eight do not survive the first year, and roughly half are alive a decade later. Holm described the coming recovery period as 'extremely delicate.' Royal historian Ole-Jørgen Schulsrud-Hansen called the successful transplant 'very happy news,' framing it as the removal of the most serious threat to her future — though the nation understands that the work of surviving has only just begun.
The transplant also follows a bruising winter for the crown family. Earlier this year, documents revealed Mette-Marit's three-year friendship with Jeffrey Epstein, prompting a public apology in which she acknowledged poor judgment. Combined with her son's conviction and her own life-threatening illness, 2026 has been an extraordinarily difficult year. Now, from a hospital bed in Oslo, she begins the slow and uncertain work of recovery — and Norway waits to see whether this second chance will hold.
Crown Princess Mette-Marit of Norway is recovering in an Oslo hospital after receiving a lung transplant, the royal household announced this week. The 52-year-old had been living with pulmonary fibrosis since 2018—a progressive lung disease that gradually stiffens the tissue and makes breathing harder. In recent months, her condition had accelerated sharply. By mid-May, when she last appeared in public, she was tethered to an oxygen device via nasal tube. Twelve days before the surgery, her doctors placed her on the transplant waiting list, a designation that carries a stark clinical meaning: they believed she had roughly one year left to live without intervention.
Are Holm, the lung specialist overseeing her care, confirmed in a palace statement that the transplant proceeded without complication. Mette-Marit will remain hospitalized for several weeks as standard protocol for all new transplant recipients, a period when the body's rejection response is most volatile and closest monitoring is essential. Prince Haakon, her husband, has begun adjusting his official duties to be present during her recovery.
The surgery arrives amid turbulent circumstances for the Norwegian royal family. Just two days earlier, Mette-Marit's adult son, Marius Borg Høiby, was sentenced to four years in prison after conviction on rape charges. Høiby, 29, is not a royal himself—he was four years old when his mother married the crown prince in 2001—but the timing of his sentencing and incarceration cast a shadow over what should have been a moment of medical relief. His legal team had repeatedly petitioned for his temporary release so he could support his mother during her health crisis, but those requests were denied.
The road to transplant has been long and increasingly desperate. Holm had publicly warned earlier this year that Mette-Marit's deterioration was "significant" and "dangerous." As her lung function declined, she systematically withdrew from public engagements, a visible signal to Norwegians that their crown princess was in serious trouble. The diagnosis itself—a rare form of pulmonary fibrosis—offered no cure, only management and, eventually, the possibility of a donor organ if one became available in time.
What comes next is medically precarious. Transplant recipients must take immunosuppressive drugs for the rest of their lives to prevent their immune system from attacking the foreign tissue. The statistics are sobering: one in eight people who receive a donor lung do not survive the first year. About half remain alive a decade after transplant. Holm stressed that the recovery period ahead will be "extremely delicate," requiring constant vigilance and careful adjustment of medications.
Royal historian Ole-Jørgen Schulsrud-Hansen called the successful transplant "very happy news" for both the family and the nation, describing it as removal of "one of the most serious obstacles" to the crown princess's future. The relief in his words reflects the weight of what Mette-Marit faced: a disease with no reversal, only decline, until a donor became available and surgery could be performed.
The transplant also arrives after a difficult winter for the royal household. In January, documents surfaced revealing Mette-Marit's three-year friendship with Jeffrey Epstein, the late financier and convicted sex offender. She later apologized publicly, acknowledging "poor judgement" and expressing regret that she had ever known him. That controversy, combined with her son's criminal conviction and her own life-threatening illness, has made 2026 an exceptionally challenging year for Norway's crown family. Now, as Mette-Marit begins the slow, uncertain work of recovery in a hospital bed, the nation watches to see whether the transplant will give her the years her doctors believe she has lost.
Citações Notáveis
We are delighted that everything has progressed well so far.— Are Holm, lung specialist
This was one of the most serious obstacles on the road for a better health for the Crown Princess, and I think many people are relieved the transplant was successful.— Ole-Jørgen Schulsrud-Hansen, royal historian
A Conversa do Hearth Outra perspectiva sobre a história
What does it mean that she was placed on the list only twelve days before surgery? That seems remarkably fast.
It means her doctors believed she was running out of time. The standard rule is that you only go on the list if you're expected to have about a year left without a transplant. So when they listed her, they were saying: this woman will not survive another year with her current lungs. A donor became available almost immediately after.
And now she has to take drugs for the rest of her life to keep her body from rejecting the new lungs?
Yes. The immune system sees a foreign organ as a threat and tries to destroy it. The drugs suppress that response, but they come with their own risks—infections, other complications. It's a lifelong balance.
The statistics you mention—one in eight don't make it through the first year. That's a significant risk.
It is. But the alternative was certain death within months. For someone in her position, the transplant was the only real option.
Her son was sentenced to prison just two days before this surgery. How does that factor into her recovery?
It adds emotional weight to an already fragile moment. He's her son. She's in a hospital bed, immunocompromised, needing to focus entirely on healing. And he's in a cell. His legal team tried to get him released temporarily so he could be with her, but that was denied. It's a collision of family crisis and medical crisis.
What happens now?
Weeks of careful observation in the hospital. Then, if all goes well, a long process of learning to live with the new lungs while managing the medications and watching for any sign of rejection. It's not a cure. It's a reprieve—and a fragile one.